Recently, the Category 1 innovative drug Cofrogliptin Tablets (trade name: 倍长平) of Haisco Pharmaceutical Group Co., Ltd. is approved for marketing by China NMPA. It is indicated for improving the blood glucose control for adult patients with type 2 diabetes.

Cofrogliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, can inhibit DPP-4 activity and increase the plasma concentration of glucagon-like peptide-1 (GLP-1) and glucose dependent insulin-like polypeptide (GIP) to reduce blood glucose by increasing insulin release in a glucose dependent manner and decreasing glucagon. The marketing of this drug provides a new treatment option for adult patients with type 2 diabetes.